Literature DB >> 22478934

Stability of celecoxib oral suspension.

Ronald F Donnelly1, Elena Pascuet, Carmen Ma, Régis Vaillancourt.   

Abstract

BACKGROUND: Celecoxib is a selective cyclo-oxygenase 2 inhibitor that relieves pain without affecting platelet function, causing gastrointestinal toxic effects, or increasing the risk of bleeding.
OBJECTIVES: To develop a suspension formulation for oral celecoxib and to determine its physical and chemical stability when packaged in amber polyvinyl chloride (PVC) bottles and stored with refrigeration (5°C) and at room temperature (23°C).
METHODS: The contents of celecoxib capsules were used to prepare a single suspension, with Ora-Blend used as the suspending and flavouring agent. The suspension (10 mg/mL) was then packaged in amber PVC bottles and stored at either 5°C or 23°C. Samples were collected on days 0, 7, 14, 21, 27, 56, and 93. Chemical stability was determined using a validated stability-indicating high-performance liquid chromatography method. At each sampling time, the suspensions were checked visually for changes in appearance (i.e., colour, layering, caking, and ease of resuspension), odour, and pH.
RESULTS: All of the suspensions were stable for at least 93 days, regardless of storage conditions. There were no apparent changes in physical appearance, nor were there any substantial changes in odour or pH.
CONCLUSIONS: Suspensions of celecoxib (10 mg/mL in Ora-Blend) packaged in amber PVC bottles were stable for up to 93 days when stored at 5°C or 23°C. A 3-month expiry date has been established for this oral suspension on the basis of physical compatibility and chemical stability.

Entities:  

Year:  2009        PMID: 22478934      PMCID: PMC2827017          DOI: 10.4212/cjhp.v62i6.844

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  6 in total

1.  A stability-indicating HPLC method to determine Celecoxib in capsule formulations.

Authors:  Pramod M Dhabu; Krisnacharya G Akamanchi
Journal:  Drug Dev Ind Pharm       Date:  2002-08       Impact factor: 3.225

2.  A new stability--indicating RP-HPLC method to determine assay and known impurity of Celecoxib API.

Authors:  A S Jadhav; M S Shingare
Journal:  Drug Dev Ind Pharm       Date:  2005-09       Impact factor: 3.225

Review 3.  Stability of pharmaceuticals.

Authors:  J A Mollica; S Ahuja; J Cohen
Journal:  J Pharm Sci       Date:  1978-04       Impact factor: 3.534

4.  Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.

Authors:  L I Bebawy; A A Moustafa; N F Abo-Talib
Journal:  J Pharm Biomed Anal       Date:  2002-02-01       Impact factor: 3.935

5.  Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial.

Authors:  Elina Nikanne; Hannu Kokki; Juha Salo; Timo-Jussi Linna
Journal:  Otolaryngol Head Neck Surg       Date:  2005-02       Impact factor: 3.497

Review 6.  Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children.

Authors:  Hannu Kokki
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  6 in total
  2 in total

1.  Limited Influence of Excipients in Extemporaneous Compounded Suspensions.

Authors:  Eli Dijkers; Valerie Nanhekhan; Astrid Thorissen; Diego Marro; Marta Uriel
Journal:  Hosp Pharm       Date:  2017-07-13

2.  Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study.

Authors:  Kimmo Murto; Christine Lamontagne; Colleen McFaul; Johnna MacCormick; Kelly-Ann Ramakko; Mary Aglipay; David Rosen; Regis Vaillancourt
Journal:  Can J Anaesth       Date:  2015-04-07       Impact factor: 5.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.